• Impact Therapeutics proposed a 2026 share award (existing shares) scheme, subject to shareholder approval at an extraordinary general meeting.
• Plan uses existing H shares bought in the market by a trustee, funded from group internal resources; participants may pay a purchase price set at grant.
• Scheme mandate cap set at 5% of issued shares, excluding treasury shares, measured on the adoption date.
• Ten-year term from the adoption date unless ended earlier; unvested awards can lapse on disqualification, with clawback for misconduct.
• Board discretion covers grant terms, vesting conditions, performance targets, service conditions, clawback provisions, and change-in-control vesting timing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Therapeutics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260710-12241759), on July 10, 2026, and is solely responsible for the information contained therein.